Profile data is unavailable for this security.
About the company
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
- Revenue in USD (TTM)8.88bn
- Net income in USD440.29m
- Incorporated1987
- Employees23.83k
- LocationGrifols SAParque Empresarial Can Sant JoanAvinguda de la Generalitat, 152-158SANT CUGAT DEL VALLES 08174SpainESP
- Phone+34 935712200
- Fax+34 938008000
- Websitehttps://www.grifols.com/
More ▼
Mergers & acquisitions
| Acquired company | GRF.P:MCE since announced | Transaction value |
|---|---|---|
| Immunotek Biocenters LLC-Plasma Centers(6) | -27.26% | 62.42m |
Data delayed at least 15 minutes, as of Mar 02 2026 16:40 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals Inc | 251.23m | 48.58m | 3.90bn | 68.00 | 95.44 | 4.10 | 47.14 | 15.54 | 2.08 | 2.08 | 12.77 | 48.34 | 0.2066 | 1.01 | 5.47 | 3,694,603.00 | 4.00 | 1.82 | 4.09 | 1.92 | 94.27 | 82.57 | 19.34 | 10.30 | 24.30 | -- | 0.3192 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| Indivior Pharmaceuticals, Inc | 1.18bn | 122.00m | 4.09bn | 1.03k | 34.11 | -- | 27.65 | 3.47 | 0.9592 | 0.9592 | 9.20 | -1.66 | 0.8194 | 1.03 | 4.63 | 1,145,631.00 | 8.68 | -1.36 | 26.23 | -2.98 | 85.51 | 84.87 | 10.59 | -2.47 | 0.7938 | 9.33 | 2.80 | -- | 8.69 | 8.64 | 101.55 | -56.87 | 34.66 | -- |
| Amneal Pharmaceuticals Inc | 2.93bn | 5.90m | 4.34bn | 8.10k | 835.96 | -- | 14.56 | 1.48 | 0.0165 | 0.0165 | 9.17 | -0.3483 | 0.8313 | 3.07 | 3.59 | 362,340.60 | 1.63 | -2.12 | 2.32 | -2.68 | 36.76 | 35.94 | 1.96 | -3.47 | 1.42 | 1.47 | 1.02 | -- | 16.73 | 11.43 | -39.16 | -- | -5.10 | -- |
| TG Therapeutics Inc | 531.90m | 447.47m | 4.78bn | 374.00 | 10.83 | 7.69 | 10.67 | 8.98 | 2.78 | 2.78 | 3.29 | 3.91 | 0.6603 | 0.6733 | 2.79 | 1,573,663.00 | 55.55 | -42.93 | 67.33 | -52.55 | 85.34 | -- | 84.13 | -142.45 | 2.89 | 3.77 | 0.2878 | -- | 40.80 | 364.59 | 84.52 | -- | -19.24 | -- |
| Mirum Pharmaceuticals Inc | 521.31m | -23.36m | 5.57bn | 369.00 | -- | 15.22 | 6,321.14 | 10.68 | -0.4783 | -0.4783 | 10.07 | 6.06 | 0.6889 | 4.24 | 5.17 | 1,412,770.00 | -3.09 | -19.72 | -3.96 | -23.84 | 80.77 | 78.68 | -4.48 | -43.34 | 2.55 | -13.32 | 0.4961 | -- | 54.74 | -- | 73.43 | -- | 33.50 | -- |
| PTC Therapeutics, Inc. | 1.73bn | 682.64m | 5.64bn | 991.00 | 8.78 | -- | 7.82 | 3.26 | 7.77 | 7.77 | 20.73 | -2.52 | 0.7518 | 0.9143 | 10.18 | 1,746,372.00 | 29.66 | -14.19 | 44.70 | -19.65 | 97.28 | 94.76 | 39.44 | -29.50 | 2.27 | 5.24 | 1.09 | -- | 114.51 | 35.37 | 287.90 | -- | -13.07 | -- |
| Rhythm Pharmaceuticals Inc | 189.76m | -201.92m | 6.33bn | 414.00 | -- | 44.81 | -- | 33.37 | -3.11 | -3.11 | 2.92 | 4.02 | 0.435 | 0.8762 | 8.51 | 458,350.30 | -45.05 | -50.41 | -60.38 | -61.35 | 89.73 | 89.41 | -103.57 | -210.46 | 4.16 | -36.30 | 0.286 | -- | 45.83 | -- | 23.68 | -- | 34.81 | -- |
| Grifols SA - ADR | 8.88bn | 440.29m | 7.71bn | 23.83k | 14.11 | 1.01 | 7.25 | 0.868 | 0.645 | 0.645 | 13.02 | 9.00 | 0.3746 | 1.35 | 7.15 | 372,640.50 | 2.28 | 1.72 | 2.99 | 2.21 | 39.09 | 38.85 | 6.09 | 5.43 | 0.9283 | 2.52 | 0.5621 | -- | 9.41 | 7.18 | 270.81 | -24.15 | -2.07 | -- |
| Krystal Biotech Inc | 389.13m | 204.83m | 8.06bn | 295.00 | 40.30 | 6.60 | 38.27 | 20.71 | 6.84 | 6.84 | 13.00 | 41.78 | 0.3257 | 0.6882 | 3.35 | 1,319,085.00 | 17.14 | 2.46 | 18.75 | 2.63 | 94.08 | -- | 52.64 | 13.06 | 9.56 | -- | 0.00 | 0.00 | 33.94 | -- | 129.74 | -- | -4.24 | -- |
| Halozyme Therapeutics, Inc. | 1.40bn | 316.89m | 8.21bn | 423.00 | 27.91 | 167.77 | 20.26 | 5.88 | 2.49 | 2.49 | 11.38 | 0.4144 | 0.6087 | 1.44 | 3.73 | 3,301,681.00 | 13.81 | 19.86 | 14.83 | 21.98 | 83.62 | 81.56 | 22.69 | 37.92 | 3.66 | -- | 0.9777 | 0.00 | 37.55 | 39.16 | -28.64 | 19.68 | 159.51 | -- |
| Axsome Therapeutics Inc | 638.50m | -183.17m | 8.38bn | 925.00 | -- | 94.45 | -- | 13.13 | -3.69 | -3.69 | 12.84 | 1.74 | 1.01 | 2.17 | 3.48 | 690,265.90 | -29.11 | -51.00 | -56.42 | -77.57 | 92.56 | -- | -28.69 | -76.38 | 1.48 | -25.78 | 0.6878 | -- | 65.55 | -- | 36.22 | -- | 59.92 | -- |
Data as of Mar 02 2026. Currency figures normalised to Grifols SA's reporting currency: US Dollar USD
40.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Brandes Investment Partners LPas of 31 Dec 2025 | 30.95m | 11.84% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 22.92m | 8.77% |
| Permian Investment Partners LPas of 31 Dec 2025 | 18.19m | 6.96% |
| Black Creek Investment Management, Inc.as of 31 Dec 2025 | 9.26m | 3.54% |
| Millennium Management LLCas of 31 Dec 2025 | 7.12m | 2.72% |
| BMO Asset Management Corp.as of 31 Dec 2025 | 4.26m | 1.63% |
| Merrill Lynch International (Investment Management)as of 31 Dec 2025 | 4.26m | 1.63% |
| Janus Henderson Investors UK Ltd.as of 31 Dec 2025 | 3.42m | 1.31% |
| Armistice Capital LLCas of 31 Dec 2025 | 2.77m | 1.06% |
| Arrowstreet Capital LPas of 31 Dec 2025 | 2.74m | 1.05% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
